Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against Mycobacterium tuberculosis

Yiming Kou1, Mingming Wan1, Wei Shi1, Jie Liu1, Zhilei Zhao1, Yongqing Xu1, Wei Sun1,2, Feng Gao1,2, Linjun Cai1,2*, and Chunlai Jiang1,2*

1National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, P.R. China
2Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Science, Jilin University, Changchun 130012, P.R. China

Introduction

Tuberculosis (TB) remains a serious global health issue. It caused illness in 10.4 million people and accounted for 1.3 million deaths in 2016 [1]. Bacillus Calmette-Guérin (BCG), the only anti-TB vaccine currently licensed, has been used worldwide since 1921, but its efficacy varies wildly among different populations. The efficacy of BCG for fighting adult pulmonary TB is reportedly limited, and the vaccine may potentially interfere with the tuberculin skin test...
reactivity [2]. The situation has been further complicated with the increased prevalence of drug-resistant and multidrug-resistant TB [3]. Therefore, a more effective vaccine against TB is urgently needed that would prevent drug-resistant TB in all age groups [4–6].

Currently, a few new types of vaccines to prevent TB disease are under development, including subunit vaccines, DNA vaccines, and viral vector-based vaccines. A robust cellular immunity is necessary for *Mycobacterium tuberculosis* (M.tb) since it is an intracellular pathogen. Therefore, enhancing the cellular immunity is a strategy for more effective vaccine development against M.tb [7]. HyVac and Hybrid56 are two vaccines in phase II clinical trials. Both of them are recombinant fusion proteins and use the adjuvant IC31, which can induce potent cellular immune responses via Toll-like receptor 9. Besides the cellular immunity induced by a particular adjuvant, viral-based vaccines also can induce cellular immune responses inherently. The recombinant adenovirus (Ad) vaccine and genetically modified vaccinia virus Ankara (MVA) vaccine are the two major forms of viral vector-based vaccines, and several variations of these vaccines are currently making their way to clinical trials [8–11].

The Ag85 complex, ESAT6, and TB10.4 are major antigens of M.tb and have been ascertained as the most potent antigen species for TB vaccine design [12]. All of them have been chosen as antigens for vaccine design [13–15]. The Ag85 complex containing Ag85B, Ag85A, and Ag85C is the most abundant set of antigens in the culture supernatant of mycobacteria, accounting for almost half of the total amount of extracellular proteins, with the Ag85B protein corresponding to 22%, the Ag85A protein corresponding to 15%, and the Ag85C protein corresponding to 8% [16]. Therefore, Ag85B is the primary extracellular protein of M.tb. It is likely that Ag85B is more important than Ag85A and Ag85C because of its abundant secretion compared with the other members of this complex and its presence in the culture after 3 days [17]. Several studies have shown that the Ag85B-ESAT6 fusion protein-based vaccine is an effective vaccine for tuberculosis prevention [18–20]. However, because ESAT6 is a valuable reagent for TB diagnostics, identifying a novel vaccine that does not involve the ESAT6 protein is a priority [21].

The vaccination regimen is an important factor that can influence the efficacy of a vaccine. In our previous study, we evaluated heterologous prime-boost regimens by priming with BCG or recombinant BCG and boosting with recombinant MVA and/or Ad. We found that boosting mice with Ad85B-ESAT6 and MVA85B-ESAT6 vaccines could strengthen the BCG-induced immune protective effect [7]. These data imply that the immunization regimen has some impact on TB vaccine efficacy. However, our study described results in BCG-primed mice. Without BCG priming, the performance of different prime-boost immune regimens of Ad and MVA expressing the Ag85B-TB10.4 vaccines against M.tb have not been evaluated yet.

Therefore, in the present study, we selected Ag85B and TB10.4 as vaccine antigens because these proteins are promising vaccine candidates against TB and a vaccine HyVac4 based on a TB10.4 and Ag85B fusion protein is currently in clinical trials [22–24]. Next, we constructed two viral vector-based vaccines (recombinant Ad and MVA expressing the Ag85B-TB10.4 fusion protein, named AdH4 and MVAH4, respectively) and evaluated the performance of the various prime-boost immune regimens of these two vaccines.

### Materials and Methods

#### Construction of MVAH4 and AdH4

The recombinant MVA expressing the Ag85B-TB10.4 fusion protein (MVAH4) was constructed and purified as described previously [25]. The recombinant replication-defective Ad expressing Ag85B-TB10.4 (AdH4) was constructed according our previous work by using the AdMax Adenovirus Creation Kit (MicrobixBiosystems, Canada) [26]. Briefly, the Ag85B-TB10.4 fusion gene was cloned into pDC316. Then, pDC316-Ag85B-TB10.4 was co-transfected with genomic plasmid (pBHGlox∆E1, 3Cre) into HEK-293 cells and the AdH4 was rescued by homologous recombination. The virus was stored at −80°C and the titers were determined as TCID₅₀ on HEK-293 cells before immunization.

#### Antigen Proteins and Peptides

The recombinant Ag85B and TB10.4 proteins were produced by *Escherichia coli*. The antigen peptides of Ag85B (9-1p, 9-2p, 18-1p, and 18-2p) and TB10.4 (P2, P3, P7, and P8) were synthesized by GL Biochem (China) [26, 27].

#### Immunization

Female BALB/c mice were procured from Changsheng Biotechnology Co. LTD (China), randomly assigned into six groups (5 mice per group), and kept in individual ventilated cages at the Experimental Animal Center Laboratory of Jilin University. Mice were subcutaneously (s.c.) injected once at the base of the thighs with BCG (1 × 10⁶ CFU) or twice with viral vector vaccines (1 × 10⁶ pfu MVAH4 s.c. or 1 × 10⁶ pfu AdH4 intramuscularly) at 2-week intervals. The vaccine regimens are described in detail in Fig 1. All the animal experiments were approved by the Institutional Animal Care and Use Committee of Jilin University.
**Enzyme-Linked Immunosorbent Assay (ELISA)**

ELISA was carried out for the measurement of antigen-specific antibodies. The 96-well plates were coated with 5 μg/ml (100 μl/well) recombinant Ag85B or TB10.4 protein and incubated overnight. The 50-fold diluted sera in PBS containing 1% bovine serum albumin was added to each antigen-coated well, and then 1:1000 diluted secondary antibodies (HRP-conjugated rabbit anti-goat IgG) were applied and revealed using TMB substrate. MVAH4: recombinant modified vaccinia virus Ankara expressing the Ag85B-TB10.4 fusion protein.

**Statistical Analyses**

Data are presented as the mean ± SD, and the Student’s t-test was performed for independent samples. For the above statistical analysis, GraphPad Prism 7 was used. P values less than 0.05 were considered significant.

**Results**

**Antigen-Specific Antibody Responses Elicited by Different Vaccine Regimens**

In order to evaluate the humoral immune response induced by the vaccines, antigen-specific antibody levels in mouse sera were measured by ELISA. As shown in Fig. 2, the levels of anti-Ag85B and anti-TB10.4 IgG, IgG2a, and IgG1 in all mice immunized with the viral vector-based vaccines were significantly higher than those in BCG-immunized mice. Furthermore, the heterologous prime-boost immunization regimens (AdH4-MVAH4 or MVAH4-AdH4) and the AdH4-AdH4 homologous prime-boost regimen induced significantly stronger antigen-specific antibody responses than that by homologous MVAH4-MVAH4 vaccination. No significant change in the IgG2a/IgG1 ratio was observed among all the groups. These data indicate that both viral vector-based vaccines can induce mouse humoral immune response against Ag85B-TB10.4, and all these vaccines elicited a balanced Th1 and Th2 immune response.
IFN-γ-producing splenocytes were produced than other peptide-sensitive IFN-γ-producing splenocytes in the BCG-immunized mice, which is similar to previous studies [27]. Furthermore, the

Fig. 2. Levels of antigen-specific antibodies (total IgG, IgG1, and IgG2a) and the ratio of IgG2a/IgG1.
(A) OD<sub>450</sub> values of antigen-specific total IgG, IgG1, and IgG2a. Serum samples were collected on day 28 from immunized mice and the levels of Ag85B- or TB10.4-specific IgG, IgG1, and IgG2a were measured by ELISA. The serum samples were diluted 50-fold with assay buffer. **p < 0.01; ***p < 0.001. (B) Ratio of IgG2a/IgG1.

Fig. 3. Results of the IFN-γ ELISpot assay.
The frequencies of antigen-specific IFN-γ-secreting cells were assayed ex vivo via the IFN-γ ELISpot assay using freshly isolated splenocytes on day 28. Data shown are the mean ± standard deviation for two independent assays.
number of IFN-γ-producing splenocytes that were sensitive to CD8 T-cell restricted peptides of Ag85B (9-1p and 9-2p) in the AdH4-MVAH4 heterologous prime-boost regimen-immunized group was significantly higher than that in the other viral vector-based vaccine-immunized groups. These data imply that the Ad-based vaccines might have a higher capacity to induce mice cellular immune responses against TB than BCG and MVAH4 vaccines.

**CD69 Surface Expression on T cells**

In order to characterize the phenotype of antigen-specific activated T cells, splenocytes were stimulated with or without the antigens in vitro, and the expression of CD3, CD4, CD8, and CD69 was analyzed by flow cytometry analysis. As shown in Fig. 4, compared with the BCG immunized group, Ag85B stimulation could significantly increase the populations of CD69^+CD8^+ T cells in the viral vector-based vaccine-immunized groups. The TB10.4 stimulation could significantly increase the populations of CD69^+CD8^+ T cells in the AdH4-AdH4, MVAH4-AdH4, and AdH4-MVAH4-immunized groups when comparing with the BCG-immunized group. Both Ag85B and TB10.4 stimulations could slightly increase the populations of CD69^+CD8^+ T cells in the AdH4-AdH4, MVAH4-AdH4, and AdH4-MVAH4-immunized groups than that in the MVAH4-MVAH4-immunized group, but not significantly. After Ag85B and TB10.4 stimulations, the proportions of CD69^+CD4^+ T cells in all immunized groups were not significantly different from each other (Fig. S1). All these data indicate that the viral vector-based vaccines might have more potential to activate CD8^+ T cells than that by BCG, and the Ad-containing immunization regimens could activate CD8^+ T cells more easily than that by the MVAH4-MVAH4 vaccine regimen.

**Th1/Th2 Cytokine Profiles**

Splenocytes were stimulated with Ag85B and TB10.4 (5 μg/ml) for 48 h, and then cytokines in the culture supernatants were measured using mouse Th1/Th2 Panel Multi-analyte Flow Assay kits. Significant differences in the levels of Th1/Th2 cytokines were observed among these prime-boost immunization regimens (Table 1). We found that the levels of Th1-related cytokines (IFN-γ and TNF-α) in the AdH4-MVAH4 heterologous prime-boost regimen-immunized group were significantly higher than those in the BCG-immunized group. We also found that Ag85B stimulation can induce Th1 cytokine (IFN-γ and TNF-α) secretion at higher levels in the viral vector-based vaccine-immunized mice than in BCG-immunized mice. Additionally, the levels of IFN-γ in mice that had been administered vaccines containing AdH4 were significantly higher than that in MVAH4-MVAH4-immunized mice. However, the highest level of TNF-α was observed in MVAH4-MVAH4-immunized mice. Similar secretion patterns of IFN-γ and TNF-α were observed when mice were stimulated with TB10.4. Table 1 also shows that Ag85B...
stimulation can slightly increase the secretion of IL-4 and IL-10 and significantly increase the secretion of IL-5 and IL-6 in the AdH4-MVAH4 group compared with that in the BCG group. However, TB10.4 significantly decreased the secretion of IL-4 and IL-10 in the viral vector-based vaccine-immunized groups relative to that in the BCG group. These data suggested that the characteristics of cytokine secretion in different immunized groups induced by Ag85B and TB10.4 stimulation are diverse. The Ad-containing vaccine regimens might induce IFN-γ-mediated immunity more easily than that by the MVAH4-MVAH4 vaccine regimen, and the AdH4-MVAH4 prime-boost regimen may induce a stronger Th1-mediated immune response than that by BCG.

**Discussion**

We developed two viral vector-based vaccines expressing an Ag85B-TB10.4 fusion protein, AdH4 and MVAH4, and investigated the impact of various prime-boost immunization regimens on the efficacy of these vaccines. We found that these vaccines can induce the production of significantly higher levels of antigen-specific antibodies, IFN-γ-producing splenocytes, and CD69+CD8+ T cells, and IFN-γ secretion when compared with that by the BCG-immunized mice. These results are in line with those reported by previous studies [13, 28].

In our previous study, we evaluated heterologous prime-boost regimens by priming with BCG or recombinant BCG and boosting with recombinant MVA and/or Ad. We found that boosting mice with Ad85B-ESAT6 and MVA85B-ESAT6 vaccines can strengthen the BCG-induced immune protective effect [7]. In this study, we found that the AdH4-containing vaccine immunization regimens (AdH4-AdH4, AdH4-MVAH4, and MVAH4-AdH4) induced significantly stronger antibody responses, higher production levels of IFN-γ-producing splenocytes and CD69+CD8+ T cells, and higher levels of IFN-γ secretion compared with MVAH4-MVAH4 immunization. The results indicate that an immunization regimen containing AdH4 may have a higher capacity to induce mice humoral and cellular immune responses against TB than immunization regimens containing BCG or MVAH4 alone. Previous studies showed that repeated homologous immunization can reduce the breadth of immune responses, whereas a heterologous prime-boost regimen can generate a comprehensive immune response against *Plasmodium falciparum* TRAP [29]. Here, we found that levels of Th1-related cytokines (IFN-γ and TNF-α) in the AdH4-MVAH4- and MVAH4-MVAH4-immunized groups were significantly higher than those in the BCG-immunized groups. However, the AdH4-MVAH4-immunized mice showed significantly higher levels of IFN-γ than MVAH4-MVAH4-immunized mice. Additionally, only IFN-γ secretion was elevated significantly by AdH4-AdH4 and MVAH4-AdH4 immunization. The number of IFN-γ-producing splenocytes sensitive to CD8+ T-cell restricted peptides of Ag85B (9-1p and 9-2p) in the AdH4-MVAH4-immunized group was significantly higher than that in other viral vector-based vaccine-immunized groups. Previous

**Table 1. Th1/Th2 cytokine profiles.**

<table>
<thead>
<tr>
<th>Stimulation</th>
<th>Cytokines</th>
<th>BCG</th>
<th>MVAH4-MVAH4</th>
<th>AdH4-AdH4</th>
<th>MVAH4-AdH4</th>
<th>AdH4-MVAH4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ag85B</td>
<td>IFN-γ</td>
<td>73 ± 35</td>
<td>1032 ± 8*</td>
<td>15,480 ± 538*</td>
<td>11,971 ± 56*</td>
<td>6,168 ± 361*</td>
</tr>
<tr>
<td></td>
<td>TNF-α</td>
<td>1.75 ± 0.37</td>
<td>19.02 ± 0.13*</td>
<td>2.41 ± 0.13</td>
<td>2.17 ± 0.13</td>
<td>17.08 ± 2.29*</td>
</tr>
<tr>
<td></td>
<td>IL-4</td>
<td>36 ± 2.0</td>
<td>3 ± 0.2</td>
<td>78 ± 4.7*</td>
<td>70 ± 3.6*</td>
<td>43 ± 8.1</td>
</tr>
<tr>
<td></td>
<td>IL-5</td>
<td>322 ± 33.9</td>
<td>126.5 ± 4.5</td>
<td>5,508 ± 197*</td>
<td>4,283 ± 383*</td>
<td>1,427 ± 55*</td>
</tr>
<tr>
<td></td>
<td>IL-6</td>
<td>37 ± 2.3</td>
<td>207 ± 4.1*</td>
<td>196 ± 12.1*</td>
<td>167 ± 6.9*</td>
<td>239 ± 14*</td>
</tr>
<tr>
<td></td>
<td>IL-10</td>
<td>39 ± 3.1</td>
<td>57 ± 3.2</td>
<td>49 ± 3.8</td>
<td>32 ± 2.3</td>
<td>42 ± 6.2</td>
</tr>
<tr>
<td>TB10.4</td>
<td>IFN-γ</td>
<td>9,345 ± 315</td>
<td>1,058 ± 35*</td>
<td>16,841 ± 537*</td>
<td>16,856 ± 414*</td>
<td>12,957 ± 375*</td>
</tr>
<tr>
<td></td>
<td>TNF-α</td>
<td>2.62 ± 0.18</td>
<td>13.81 ± 1.82*</td>
<td>2.14 ± 0.13</td>
<td>1.09 ± 0.18</td>
<td>12.40 ± 0.20*</td>
</tr>
<tr>
<td></td>
<td>IL-4</td>
<td>384 ± 17</td>
<td>30 ± 0.7*</td>
<td>96 ± 3.6*</td>
<td>63 ± 3.4*</td>
<td>90 ± 4.8*</td>
</tr>
<tr>
<td></td>
<td>IL-5</td>
<td>5,111 ± 46</td>
<td>113 ± 5.2*</td>
<td>5,071 ± 203</td>
<td>5,371 ± 189</td>
<td>3,799 ± 21*</td>
</tr>
<tr>
<td></td>
<td>IL-6</td>
<td>110 ± 4.6</td>
<td>134 ± 17.4</td>
<td>101 ± 2.9</td>
<td>134 ± 5.7</td>
<td>149 ± 10.2</td>
</tr>
<tr>
<td></td>
<td>IL-10</td>
<td>100 ± 2.5</td>
<td>27 ± 2.7*</td>
<td>33 ± 1.2*</td>
<td>21 ± 1.5*</td>
<td>27 ± 3.5*</td>
</tr>
</tbody>
</table>

Results represent the mean and SD of five animals per group. Asterisks indicate significant difference in cytokine secretion compared with the BCG-immunized group (p value <0.05, Student’s t-test). Unit: pg/ml.
studies report that the Th1-mediated immune response and CD8+ T lymphocytes are essential for the containment of M. tuberculosis infection [30]. These data imply that the heterologous prime-boost regimens using AdH4 for priming followed by boosting with MVAH4 may enhance the protective efficacy. However, one limitation of our study is that the immune protective effect of these vaccines and the various immunization regimens against M. tuberculosis infection have not been evaluated.

Several factors may affect the immune efficacy of AdH4 and MVAH4, such as the profile of antigen expression, the persistence of antigen, and the type of dendritic cells [31]. Previous studies have tried to explore the reason for the differences between immune responses elicited by Ad5- and MVA-based vaccines and they found some inconsistent results [31–33]. Maeda et al. [32] reported that the Ad vector elicits more antigen-specific IFN-γ-producing T cells despite producing less antigen expression. However, Pillai et al. [31] found that the Ad5 vector can prime 6-fold higher levels of antigen-specific CD8 effector T cells than the MVA vector, but the difference of the antigen expression between Ad- and MVA-infected cells is not significant. Therefore, the mechanism for the immune response induced by these two viral-based vectors is complicated, and the detail and precise reason for why AdH4-containing immunization has a higher capacity to induce immune responses than MVAH4 alone needs to be further investigated.

In conclusion, both AdH4- and MVAH4-based vaccines can induce a humoral immune response against Ag85B-TB10.4 in mice, and all these vaccines elicited a balanced Th1 and Th2 immune response. Moreover, the Ad-based vaccines might have a higher capacity to induce mouse cellular immune responses against TB than the BCG and MVAH4 vaccines.

Acknowledgments

This work was supported by the National Natural Science Foundation (Grant No. 81401717) of P. R. China.

Conflict of Interest

The authors have no financial conflicts of interest to declare.

References


